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Abstract
Background: The HELLP syndrome is a serious complication in pregnancy characterized by
haemolysis, elevated liver enzymes and low platelet count occurring in 0.5 to 0.9% of all pregnancies
and in 10–20% of cases with severe preeclampsia. The present review highlights occurrence,
diagnosis, complications, surveillance, corticosteroid treatment, mode of delivery and risk of
recurrence.
Methods: Clinical reports and reviews published between 2000 and 2008 were screened using Pub
Med and Cochrane databases.
Results and conclusion: About 70% of the cases develop before delivery, the majority between
the 27th and 37th gestational weeks; the remainder within 48 hours after delivery. The HELLP
syndrome may be complete or incomplete. In the Tennessee Classification System diagnostic
criteria for HELLP are haemolysis with increased LDH (> 600 U/L), AST (≥ 70 U/L), and platelets
< 100·109/L. The Mississippi Triple-class HELLP System further classifies the disorder by the nadir
platelet counts. The syndrome is a progressive condition and serious complications are frequent.
Conservative treatment (≥ 48 hours) is controversial but may be considered in selected cases < 34
weeks' gestation. Delivery is indicated if the HELLP syndrome occurs after the 34th gestational
week or the foetal and/or maternal conditions deteriorate. Vaginal delivery is preferable. If the
cervix is unfavourable, it is reasonable to induce cervical ripening and then labour. In gestational
ages between 24 and 34 weeks most authors prefer a single course of corticosteroid therapy for
foetal lung maturation, either 2 doses of 12 mg betamethasone 24 hours apart or 6 mg or
dexamethasone 12 hours apart before delivery. Standard corticosteroid treatment is, however, of
uncertain clinical value in the maternal HELLP syndrome. High-dose treatment and repeated doses
should be avoided for fear of long-term adverse effects on the foetal brain. Before 34 weeks'
gestation, delivery should be performed if the maternal condition worsens or signs of intrauterine
foetal distress occur. Blood pressure should be kept below 155/105 mmHg. Close surveillance of
the mother should be continued for at least 48 hours after delivery.
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Background
It has been known for a long time that preeclampsia may
be associated with haemolysis, elevated liver enzymes and
thrombocytopenia [1]. Weinstein regarded signs and
symptoms to constitute an entity separated from severe
preeclampsia and in 1982 named the condition HELLP
(H = Haemolysis, EL = Elevated Liver enzymes, LP = Low
Platelets) syndrome [2]. The HELLP is currently regarded
as a variant of severe preeclampsia or a complication [3-
9].
Diagnosis of the complete form of the HELLP syndrome
requires the presence of all 3 major components, while
partial or incomplete HELLP syndrome consists of only 1
or 2 elements of the triad (H or EL or LP) [3,7,8,10].
The HELLP syndrome, a serious condition in its complete
form, is associated with substantial risk for the mother
and her foetus [3-6,11-14]. A wide range of complications
may arise and the condition represents diagnostic and
therapeutic problems; timing and method of delivery are
important.
The aim of this review is to present an update on maternal
clinical issues of the syndrome, with special focus on diag-
nosis, complications, surveillance, timing and mode of
delivery and risk of recurrence. Perinatal mortality and
morbidity are briefly outlined and controversial aspects of
corticosteroid (CS) treatment are particularly discussed.
Methods
A systematic literature search for clinical reports and
reviews published between 2000 and 2008 was under-
taken using Pub Med and the Cochrane databases. Search
words were "HELLP syndrome", and "HELLP syndrome"
combined with "diagnosis", respective "clinical symp-
toms", "complications", "morbidity", "mortality", "man-
agement", "treatment", "corticosteroid", "prognosis",
"delivery", "post-partum" and "recurrence". Publications
were selected for review based on original research, highly
regarded earlier publications and comprehensive reviews.
The abstracts were read and those publications considered
to be relevant were used at the authors' discretion. Some
publications have also been found in the reference list in
previous publications.
Occurrence and clinical symptoms
The HELLP syndrome occurs in about 0.5 to 0.9% of all
pregnancies and in 10 to 20% of cases with severe preec-
lampsia [15,16]. In about 70% of the cases, the HELLP
syndrome develops before delivery [14] with a peak fre-
quency between the 27th and 37th gestational weeks;
10% occur before the 27th week, and 20% beyond the
37th gestational week [6]. The mean age of pregnant
women with HELLP syndrome is usually higher than in
women with preeclampsia [3,17]. Most white women
with HELLP are multiparous [10]. In the post-partum
period the HELLP syndrome usually develops within the
first 48 hours in women who have had proteinuria and
hypertension prior to delivery [14]. Although variable, the
onset of the HELLP syndrome is usually rapid [7]. The
majority of women with the HELLP syndrome have had
hypertension and proteinuria, which may be absent in
10–20% of the cases [9]. Excessive weight gain and gener-
alized oedema precede the syndrome in more than 50%
of the cases [8].
Typical clinical symptoms are right upper abdominal
quadrant or epigastric pain, nausea and vomiting. The
upper abdominal pain may be fluctuating, colic-like
[9,18]. Many patients report a history of malaise some
days before presentation [9]. Up to 30–60% of women
have headache; about 20% visual symptoms [9]. How-
ever, women with a HELLP syndrome might also have
unspecific symptoms or subtle signs of preeclampsia or
non-specific viral syndrome-like symptoms [9]. The
symptoms usually continuously progress and their inten-
sity often changes spontaneously. The HELLP syndrome is
characterized by exacerbation during the night and recov-
ery during the day [19].
Women with partial HELLP syndrome have fewer symp-
toms and develop less complications than those with the
complete form [3]. However, a partial or incomplete
HELLP syndrome may develop to a complete form of the
disorder [7]. Partial or total reversal of the syndrome may
also occasionally occur, albeit rarely [18,20].
The triad signs of haemolysis, elevated liver enzymes and 
thrombocytopenia
Haemolysis, one of the major characteristics of the disor-
der, is due to a microangiopathic haemolytic anaemia
(MAHA). Red cell fragmentation caused by high-velocity
passage through damaged endothelium appears to repre-
sent the extent of small vessel involvement with intima
damage, endothelial dysfunction and fibrin deposition.
Presence of fragmented (schizocytes) or contracted red
cells with spicula (Burr cells) in the peripheral blood
smear reflects the haemolytic process and strongly sug-
gests the development of MAHA [6,21]. Polychromatic
red cells are also seen in blood smears, and increased retic-
ulocyte counts reflect the compensatory release of imma-
ture red cells into peripheral blood. Destruction of red
blood cells by haemolysis causes increased serum lactate
dehydrogenase (LDH) levels and decreased haemoglobin
concentrations [22,23]. Haemoglobinaemia or haemo-
globinuria is macroscopically recognizable in about 10%
of the women [24]. Liberated haemoglobin is converted
to unconjugated bilirubin in the spleen or may be bound
in the plasma by haptoglobin. The haemoglobin-hap-BMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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toglobin complex is cleared quickly by the liver, leading to
low or undetectable haptoglobin levels in the blood, even
with moderate haemolysis [22,23]. Low haptoglobin con-
centration (< 1 g/L – < 0.4 g/L) can be used to diagnose
haemolysis [23-26] and is the preferred marker of haemo-
lysis [27]. Thus, the diagnosis of haemolysis is supported
by high LDH concentration and the presence of unconju-
gated bilirubin, but the demonstration of low or undetec-
table haptoglobin concentration is a more specific
indicator.
Elevation of liver enzymes may reflect the haemolytic
process as well as liver involvement. Haemolysis contrib-
utes substantially to the elevated levels of LDH, whereas
enhanced asparate aminotransferase (AST) and alanine
aminotransferase (ALAT) levels are mostly due to liver
injury. Plasma glutathione S-transferase-a1 (α-GST or
GST-a1) may provide a more sensitive indicator for acute
liver damage than AST and ALAT, and allow earlier recog-
nition [28]. However, measurement of α-GST is not
widely available, and has not yet found its place in the
routine diagnostic procedure [24].
Thrombocytopenia (platelets (PLTs) < 150·109/L) in
pregnancy may be caused by gestational thrombocytope-
nia (GT) (59%), immune thrombocytopenic purpura
(ITP) (11%), preeclampsia (10%), and the HELLP syn-
drome (12%)[29]. PLTs < 100·109/L are relatively rare in
preeclampsia and gestational thrombocytopenia, fre-
quent in ITP and obligatory in the HELLP syndrome
(according to the Sibai definition). Decreased PLT count
in the HELLP syndrome is due to their increased con-
sumption. Platelets are activated, and adhere to damaged
vascular endothelial cells, resulting in increased platelet
turnover with shorter lifespan [21,30,31].
Diagnostic criteria
At present, there are two major definitions for diagnosing
the HELLP syndrome. In the Tennessee Classification Sys-
tem, Sibai has proposed strict criteria for "true" or "com-
plete" HELLP syndrome (Table 1) [8,9]. Intravascular
haemolysis is diagnosed by abnormal peripheral blood
smear, increased serum bilirubin (≥ 20.5 μmol/L or ≥ 1.2
mg/100 mL) and elevated LDH levels (> 600 units/L (U/
L) [8,32].
In The Mississippi-Triple Class System, a further classifica-
tion of the disorder is based on the nadir PLT count any
time during the course of the disease (Table 1) [7]. Class
1 and class 2 are associated with haemolysis (LDH > 600
U/L) and elevated AST (≥ 70 U/L) concentration, while
class 3 requires only LDH > 600 U/L and AST ≥ 40 U/L in
addition to the specific PLT count [7,33,34]. Class 3
HELLP syndrome is considered as a clinical significant
transition stage or a phase of the HELLP syndrome which
has the ability of progression [34].
The diagnosis of the HELLP syndromes has often been
based on different criteria [9]. The condition can be diag-
nosed simply on biochemical evidence [4,9,14,35-37].
Some authors require the presence of severe preeclampsia
together with biochemical substantiation to diagnose
HELLP [5,38-42]. Others deal with the HELLP syndrome
as partial or incomplete HELLP [43,44]. A number of
studies have included women with lack of suspicion or
evidence of haemolysis. The syndrome ELLP has been
described where there has been no haemolysis [15,45].
The use of different definitions makes comparison of pub-
lished data difficult [9]. According to Smulian et al. the
threshold of normal LDH values may be much lower than
600 U/L depending on the laboratory method adopted
[41]. Visser and Wallenburg used ALAT > 30 U/L to define
abnormality (2 SD above mean in hospital) [20]. Clearly,
the analytical method used is important for the diagnostic
reference range.
Differential diagnosis
The HELLP syndrome may be misdiagnosed as viral hep-
atitis, cholangitis and other acute diseases (Table 2)
[6,46]. Other less common, but serious conditions that
may mimic HELLP, include ITP, acute fatty liver of preg-
nancy (AFLP), haemolytic uremic syndrome (HUS),
thrombotic thrombocytopenic purpura (TTP) and sys-
temic lupus erythematosus (SLE) [21,32]. These condi-
tions are associated with high maternal mortality and may
cause long-term squeals [32]. They may be mistaken for a
HELLP syndrome and a careful diagnostic evaluation is
required as their therapy is quite different.
Clinical signs of AFLP vary and there is significant overlap
in clinical and biochemical features with the HELLP syn-
drome [47]. AFLP typically occurs between the 30th and
38th gestational weeks with a 1 to 2 week history of
malaise, anorexia, nausea, vomiting, mid epigastric or
right upper abdominal pain, headache and jaundice.
Hypertension and proteinuria are usually absent. Further
Table 1: Main diagnostic criteria of the HELLP syndrome
HELLP class Tennessee Classification Mississippi classification
1 Platelets ≤ 100·109/L Platelets ≤ 50·109/L
AST ≥ 70 IU/L AST or ALT ≥ 70 IU/L
LDH ≥ 600 IU/L LDH ≥ 600 IU/L
2 Platelets ≤ 100·109/L
≥ 50·109/L
AST or ALT ≥ 70 IU/L
LDH ≥ 600 IU/L
3 Platelets ≤ 150·109/L
≥ 100·109/L
AST or ALT ≥ 40 IU/L
LDH ≥ 600 IU/LBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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examination reveals haemoconcentration, metabolic aci-
dosis, acute liver failure and low grade disseminated intra-
vascular coagulation (DIC) with normal or moderately
subnormal PLT count, prolonged prothrombin time (PT)
and partial thromboplastin time (PTT), low serum fibrin-
ogen and antithrombin concentrations [32,47,48].
Abnormal blood tests also include leucocytosis, increased
levels of creatinine, uric acid, ammonium and liver
enzymes such as alkaline phosphatase, AST, ALAT and
bilirubin [32,49]. Hypoglycemia and prolongation of
prothrombin time may distinguish AFLP from the HELLP
syndrome [47]. Ultrasound examination of the liver may
reveal increased echogenicity in severe cases of AFLP.
Computerized tomography (CT) can well show decreased
or diffuse attenuation in the liver. Liver biopsy is recom-
mended as the standard procedure to confirm the diagno-
sis, but requires an acceptable haemostatic function [32].
Gastrointestinal bleeding, acute renal failure and pancre-
atitis may complicate AFLP. Most women improve in the
course of 1 to 4 weeks post-partum, but AFLP may recur in
next pregnancy [47].
ITP is a clinical syndrome with thrombocytopenia which
may be manifested as a bleeding disorder with purpura
and petechiae. Pregnancy does not increase the incidence
of ITP, nor does it exacerbate a preexisting disease. Even
with a very low platelet count there is in most cases nei-
ther maternal nor fetal morbidity or mortality [29,50,51].
HUS and TTP are thrombotic microangiopathies which
share some of the pathophysiological characteristics of
the HELLP syndrome including endothelial injury, plate-
let aggregation, microthrombi, thrombocytopenia and
anaemia [49]. Abnormal blood smear, increased LDH and
creatinine levels may help in the differentiation. The
microvascular injury in HUS affects mainly the kidneys
[32]. HUS develops usually in the post-partum period,
with signs and symptoms of renal failure [9]. However,
most cases arise in children and adolescents caused by a
specific enterotoxin produced by Escherichia coli
O157:H7. Rare forms may be due to a genetic abnormal-
ity in the complement system [52]. TTP, which is an
extremely rare condition during pregnancy, is character-
ized by neurological dysfunction, fever, abdominal pain
and bleeding. The spectrum of neurological abnormalities
spans from headache to visual disturbances, confusion,
aphasia, transient paresis, weakness and seizures. High
levels of high-molecular weight von Willebrand factor in
maternal serum reflect the virtual absence of the metallo-
protease ADAMTS13 enzyme which is required to control
the level of the factor [32,53]. Specific tests for this hered-
itary condition are not readily available in routine clinical
laboratories [32]. The mortality of HUS and TTP has
decreased due to the use of plasma exchange and intensive
care [52].
SLE is an autoimmune disorder characterized by deposits
of antigen-antibody complexes in capillaries, with mild to
severe clinical findings. SLE may affect multiple organ sys-
tems (kidneys, lungs, heart, liver and brain). The clinical
and laboratory findings in women with lupus nephritis
are similar to those with severe preeclampsia. Antiphos-
pholipid antibodies (lupus anticoagulant and/or anticar-
diolipin antibodies) are present in 30–40% of the cases,
while thrombocytopenia occurs in 40–50% and haemo-
lytic anaemia in 14–23% of the women with SLE. Cere-
Table 2: Differential diagnosis of the HELLP syndrome.
1. Diseases related to pregnancy
Benign thrombocytopenia of pregnancy
Acute fatty liver of pregnancy (AFLP)
2. Infectious and inflammatory diseases, not specifically related to pregnancy:
Virus hepatitis
Cholangitis
Cholecystitis
Upper urinary tract infection
Gastritis
Gastric ulcer
Acute pancreatitis
3. Thrombocytopenia
Immunologic thrombocytopenia (ITP)
Folate deficiency
Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS)
4. Rare diseases that may mimic HELLP syndrome
Thrombotic thrombocytopenic purpura (TTP)
Haemolytic uremic syndrome (HUS)BMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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bral lesions and symptoms may develop because of
vasculitis and/or cerebro-vascular occlusion that might
lead to seizures [32]. In the so-called antiphospholipid
syndrome (APS) antiphospholipid antibodies are associ-
ated with recurrent thrombosis (in arteries and veins) and
pregnancy loss. APS may also occur as a primary disease,
unrelated to SLE. Development of HELLP syndrome in
women with an established APS syndrome may be more
frequent than previously thought [54].
Folate deficiency is common in pregnancy, but its progres-
sion to megaloblastosis is rare. Haemolytic anaemia,
thrombocytopenia, and coagulopathy due to folate defi-
ciency may mimic the incomplete HELLP syndrome [55].
Complications of the HELLP syndrome
The HELLP syndrome is associated with both maternal
and neonatal complications. Frequencies of reported seri-
ous complications are summarized in table 3[56-77].
Laboratory thresholds that indicate more than 75% risk of
serious maternal morbidity are LDH concentration >
1400 U/L, AST > 150 U/L, ALAT > 100 U/L, and uric acid
concentration >7.8 mg/100 ml (> 460 μmol/L)[6]. Inter-
estingly, clinical symptoms, such as headache, visual
changes, epigastric pain and nausea-vomiting, have been
suggested to be better predictors of adverse maternal out-
come than laboratory parameters [57].
Spontaneous rupture of a subcapsular liver haematoma in
pregnancy is a rare, but life threatening complication that
occurs 1 in 40,000 to 1 in 250,000 deliveries [63] and
about 1% to < 2% of the cases with the HELLP syndrome.
Rupture most often occurs in the right liver lobe [9,14,61-
64]. The symptoms are sudden-onset severe pain in the
epigastric and right upper abdominal quadrant radiating
to the back, right shoulder pain, anaemia and hypoten-
sion. The condition may be diagnosed by ultrasound, CT
or magnetic resonance imaging (MRI) examination [61-
63,78]. Hepatic rupture may also occur in the post-par-
tum period [79]. A few cases of liver infarctions associated
with antiphospholipid syndrome and HELLP syndrome
have been reported [66]. Even recurrent deep vein throm-
boses and palmar skin lesions have been reported in a
woman with prothrombin gene 20210a mutation and
antiphospholipid antibodies complicated by the HELLP
syndrome [67].
More common and serious maternal complications are
abruptio placentae, DIC and subsequent severe post-par-
Table 3: Complications reported in the HELLP syndrome
Maternal complications Occurrence (%) References
Eclampsia 4–9 [56]
Abruptio placentae 9–20 [3,9,35,45,57]
DIC 5–561 [35,36,58]
Acute renal failure 7–36 [4,57,59,60]
Severe ascites 4–11 [36]
Cerebral oedema 1–8 [14,36]
Pulmonary oedema 3–10 [3,36,60]
Wound hematoma/infection2 7–14 [3,56]
Subcapsular liver hematoma Between 0.9% and <2% [9,14,61-64]
Liver rupture >200 cases or about 1.8% [45,65]
Hepatic infarction >30 cases combined with APS [66]
Recurrent thrombosis Associated with prothrombin gene 20210a mutation [67]
Retinal detachment 1 [14]
Cerebral infarction Few case reports [68-71]
Cerebral Haemorrhage 1.5–403 [3,36,70]
Maternal death 1–25 [5,11]
Foetal/neonatal complications
Perinatal death 7.4–34 [9,72,73].
IUGR 38–61 [5,72,74]
Preterm delivery4 70 (15% < 28 gestational weeks) [9]
Neonatal thrombocytopenia 5 15–50 [5,75]
RDS 5.7–40 [72,76,77]
1 depending on diagnostic criteria
2 after Caesarean section
3 in a highly selected group of patients
4 associated with increased risks of RDS, IVH and CP
5PLTs < 100·109/LBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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tum bleeding (Table 3) [5]. Bilateral permanent visual
loss associated with retinopathy (Pursher-like) is a rare
ophthalmic complication during pregnancy [80]. In the
literature there are several case reports on cerebral bleed-
ing associated with the HELLP syndrome [68-71]. In a
report by Sibai et al. on the outcome of 442 pregnancies
complicated by HELLP cerebral bleeding was not men-
tioned as a complication [14]. Audibert et al. report cere-
bral bleeding to occur in 1.5% of the cases [3]. Contrary
to this, in a highly selected group of 37 women with the
HELLP syndrome that was transferred to an obstetric
intensive care unit in Turkey, 15 women (40%) had cere-
bral haemorrhage. In this study CT and MRI were used as
diagnostic tools [36]. The risk of stroke is not increased
during pregnancy itself. However, the risk of cerebral inf-
arction and intracerebral haemorrhage is increased some
weeks after delivery [81]. This is reflected by some case
reports of cerebral infarction after delivery as a complica-
tion to the HELLP syndrome [68-71]. Life-threatening
neurological complications of the HELLP syndrome are
rare, but incorporate large cerebral or brain stem haemor-
rhage, thrombosis and infarctions or cerebral oedema
complicated by brain herniation [6]. Wound haematoma
and infection are frequent phenomena in women with the
HELLP syndrome undergoing Caesarean section [82].
DIC
Activation of vascular endothelium and of platelets,
haemolysis and liver damage are the basic pathophysio-
logical features characteristic for the HELLP syndrome,
each predisposing to DIC [83,84]. In a retrospective
cohort study, 38% of pregnant women with the HELLP
syndrome developed DIC (PLTs < 100·109/L, low serum
fibrinogen concentration (< 3 g/L), fibrin degradation
products (FDP) (>40 μg/ml = 40 mg/L) most often related
to placental abruption [45]. Low antithrombin concentra-
tion may be caused by liver dysfunction with decreased
synthesis, and by increased consumption in DIC. Pater-
noster et al. reported that women with a HELLP syndrome
had higher concentration of fibronectin and D-dimer and
lower antithrombin levels than in normal pregnancy and
in preeclampsia [85]. Abruptio placentae associated with
the HELLP syndrome increases the risk of DIC substan-
tially as well as the risk of pulmonary oedema, renal fail-
ure (oliguria, anuria, high serum creatinine levels) and the
need for blood transfusion [9,35,86]. A contributing fac-
tor for acute renal failure is microangiopathy and DIC
[4,59,60]. Visual disturbances, including retinal detach-
ment, vitreal haemorrhage and cortical blindness, are
infrequent complications in which DIC probably contrib-
utes [34].
Maternal mortality
In a large retrospective cohort study comprising 442 preg-
nancies complicated by the HELLP syndrome, the mater-
nal mortality was 1.1% [14], which is in accordance with
other reports [3,9,87,88]. However, higher maternal mor-
tality, up to 25%, has been reported [11]. Unexpected
rapid death from HELLP may require forensic expertise
[89]. Isler et al. found cerebral haemorrhage or stroke to
be the primary cause of death in 26% and the most con-
tributing factor in another 45% of the deaths [90]. Mater-
nal mortality rate in hepatic rupture ranges from 18 to
86% [91].
HELLP, perinatal mortality and morbidity
Perinatal mortality and morbidity are considerably higher
in the HELLP syndrome than that of the mothers, and are
primarily dependent on the gestational age when the con-
dition develops [74,92]. The perinatal mortality rate
related to the HELLP syndrome is between 7.4% and 34%
[9,72,73]. Neonates delivered before completed 32 weeks'
gestation have the highest risk of perinatal death [74,92].
According to Gul et al. the perinatal mortality was 34%
before 32 weeks' gestation, and 8% after the 32nd gesta-
tional week [72]. Prematurity, placental insufficiency,
with or without intrauterine growth restriction (IUGR)
and abruptio placentae, are the leading causes of neonatal
death [6,15,21]. Hepatic rupture has a perinatal mortality
that can reach 80% [91].
Neonatal thrombocytopenia occurs in between 15% and
38% of cases [5,93] and is a significant risk factor for both
intraventricular haemorrhage (IVH) and long-term neuro-
logical complications [5,94].
The neonatal outcome of the HELLP syndrome represents
a controversy [94]. Some authors report that infants born
to mothers with a HELLP syndrome are more likely to be
small for gestational age (SGA) and to have increased risk
of perinatal asphyxia and RDS [94] and that the respira-
tory and cardiovascular morbidity may be further aggra-
vated by maternal HELLP occurring before 32 weeks'
gestation [95]. A retrospective study was published in
2003 by Roelofsen et al. on the outcome of infants born
after pregnancies complicated by HELLP or ELLP syn-
drome. The gestational age was 29.9 in the HELLP group
and 30.3 weeks in the ELLP group. 64% were born before
32 weeks' gestation. Cerebral haemorrhage occurred in 3
of the infants in the HELLP group (all had thrombocyto-
penia (9–42·109/L), none in the ELLP group. After 18
months four infants belonging to the HELLP group had
major handicaps, none in the ELLP group, making a total
adverse outcome of 22.8% [44].
Other authors inform that infants born to mothers with
the HELLP syndrome are not at increased risk of morbid-
ity compared to otherwise healthy infants of the same ges-
tational age [92,93,96,97] and that that gestational age at
delivery and birth weight primarily affected the perinatalBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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mortality rather than the severity of the hypertensive dis-
ease [73]. Consequently also typical complications fol-
lowing preterm delivery in itself are reported, like
bronchopulmonary dysplasia (BPD) cerebral haemor-
rhage and persisting ductus arteriosus in HELLP [44].
Murray et al. published in 2001 the outcome of 20 cases
of the HELLP syndrome over a 5-year period. 85% were
delivered by Caesarean section within 24 hours of diagno-
sis. 65% were preterm. The mean gestation at delivery was
33.5 weeks and the mean birth weight 1923 g. 40% of the
neonates developed respiratory distress syndrome (RDS).
The neonatal morbidity was most closely related to the
gestation at delivery [77].
Analysis of the perinatal and neonatal data for women
diagnosed with HELLP from 1993 to 1996 was performed
by Singhal et al. who compared the neurodevelopmental
outcome of HELLP a group of birth weight matched con-
trols. A total of 109 infants (mean gestational age 32.6
weeks, mean birth weight 1766 g) were born by 104
women with HELLP syndrome. There were no significant
differences in gender, Apgar score, need for resuscitation,
RDS, sepsis, NEC or death in the neonatal unit, suggesting
that infants born to mothers with a HELLP syndrome are
not at increased risk for mortality or morbidity and that
the majority of neonatal complications were attributable
to prematurity [94]. There was a significant decrease in
mortality and morbidity with increasing gestational age
and birth weight. No significant differences in neonatal
mortality and morbidity were found in infants weighing
less than 1250 g compared to the weight matched control
group. At 3 years of age, the HELLP group had fewer chil-
dren with cerebral palsy (CP) and mental disability [94].
Kandler et al. reported that in the time span between 6 and
72 months (median 24 months) after delivery, 90% of
children born from mothers with HELLP showed normal
development or only minor disabilities. The mean gesta-
tional age was 33 weeks and the mean birth weight 1671
g [97]. However, the neonatal outcome is poor before 25
weeks' gestation or with birth weights less than 700 g;
after 26 weeks' gestation or in infants weighing more than
700 g it is substantially better [74,92].
We assume that differences in the outcome of the
neonates depend on the study publication and also reflect
the level of neonatal care. Infants born from mothers with
the HELLP syndrome may develop thrombocytopenia
and associated CP. However, it seems that a low gesta-
tional age at delivery is the main problem rather then
HELLP in itself. Most neonates born from a woman with
HELLP have a normal long-term development.
Management of pregnant women with HELLP syndrome
In general, there are three major options for the manage-
ment of women with severe preeclampsia and HELLP syn-
drome [7,9,72,98]. These include:
1) Immediate delivery which is the primary choice at 34
weeks' gestation or later.
2) Delivery within 48 hours after evaluation, stabilization
of the maternal clinical condition and CS treatment. At 27
to 34 weeks of gestation, this option appears appropriate
and rational for the majority of cases.
3) Expectant (conservative) management for more than
48–72 hours may be considered in pregnant women
before 27 weeks' gestation. In this situation, CS treatment
is often used, but the regimens vary considerably.
Conservative management (> 48 hours)
Large randomized clinical trials aimed to compare con-
servative versus aggressive management with immediate
delivery of women with the HELLP syndrome are missing.
However, expectant management before completed 34
weeks' gestation may be an acceptable option in selected
cases if it is performed in tertiary care units under close
maternal and foetal surveillance (e.g. antihypertensive
treatment, ultrasound and Doppler examination)
[99,100]. Possible advantages due to limited prolonga-
tion of pregnancy should be carefully weighed against the
increased risks for maternal and foetal complications
(abruptio placentae, acute renal failure, pulmonary
oedema, DIC, perinatal and maternal death) [10]. If the
maternal condition worsens, immediate Caesarean sec-
tion is inevitable [99,100]. Conservative treatment is con-
traindicated in women with DIC [58].
The benefit of temporizing management of HELLP syn-
drome is questioned [10,101]; some authors warn against
expectant management to optimize maternal condition
before delivery beyond 24–48 hours [10] or conservative
management is disregarded [73]. However, expectant
management of pregnant women with HELLP syndrome
remote from term is common practice in the Netherlands,
conditional on the safety of the mother [20,102].
Corticosteroid (CS) treatment
Promotion of foetal lung maturation in threatening preterm delivery
Irrespective of the underlying condition, preterm delivery
(< 37 weeks' gestation) carries the risk of RDS in neonates
because of insufficient surfactant production in foetal
lungs. The neonates can be treated with CS and surfactant.
Prenatal CS treatment has been shown to accelerate foetal
lung maturation through a complex interaction of hormo-
nal and intercellular signalling that leads to differentia-
tion of the surfactant lipid-protein pathway and throughBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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less well-defined increases in lung compliance [103]. The
foetal lung must be biologically ready for a CS to "trigger"
maturation. In humans this window of biological readi-
ness of the lungs seems to occur most often between 26
and 33 weeks' gestation [103].
Recently, betamethasone, instead of dexamethasone, has
been recommended as a drug of choice for promotion of
foetal lung maturation in threatening preterm delivery
[104]. In clinical trials as well as observational studies
antenatal CS treatment is associated with a decreased risk
of IVH and CP [105]. Betamethasone may be safer and
more protective of the immature brain than dexametha-
sone [106].
In a retrospective cohort study by Baud et al. comprising
883 infants with gestational age between 24 and 31 weeks
it was reported an odds ratio (OR) for cystic periventricu-
lar leucomalacia of 0.5 (95% confidence interval (CI)
0.3–0.9) for betamethasone compared with no treatment
and 1.5 (95% CI 0.8–2.9) for the dexamethasone treated
group [107]. Treatment of severe preeclampsia with beta-
methasone in the time span between 26 and 34 weeks'
gestation has been shown to significantly reduce the rate
of RDS, IVH and perinatal death in preterm delivery
[108]. A Cochrane update from 2006 advocated a single
course of antenatal CS (12 mg betamethasone twice) in
gestational ages between the 26th and 35th gestational
weeks [109]. Thus, a single course of CS is advocated in
threatening preterm delivery, including severe preeclamp-
sia.
Multiple courses are more effective, but may harm the foetus
Two randomized trials of women at risk of preterm deliv-
ery showed that weekly CS caused less RDS, less severe
neonatal lung disease and serious neonatal morbidity and
less need for mechanical respiratory support and sur-
factant use [110,111]. The short-term benefits supported
the use of repeated doses of CS in women who remain at
risk of very preterm birth 7 or more days after an initial
course. However, both studies raised serious concerns
about lower neonatal birth weight in the repeat course
group [110,111]. Two long-term follow-up studies have
been presented [112,113]. One favours the use of
repeated CS courses [112]. In the other a non-significant
higher rate of CP was detected in the repeat group (6 ver-
sus 1) and it was concluded that present findings indicate
no evident long-term benefit, rather a possible harm,
arguing that weekly administration of antenatal CS
should not be offered after an initial course [113].
Repeated CS exposure may increase mortality, restrict foe-
tal growth and cause prolonged foetal adrenal suppres-
sion [114,115]. Both repeat maternal CS exposure and
early neonatal dexamethasone treatment may cause CP in
preterm neonates [113,116,117]. An increase in the prev-
alence of CP among very preterm deliveries (time span 24
to 30 weeks of gestational age) has been reported. Postna-
tal dexamethasone treatment was associated with higher
rates of CP, whereas antenatal CS treatment was associ-
ated with lower rates [117]. Early dexamethasone treat-
ment should not be recommended for the routine
prevention or treatment of chronic lung disease [118].
CS treatment for the women with HELLP syndrome
Whereas delivery is the mainstay of treatment for the
HELLP syndrome, CS treatment is a possible addendum.
Present alternatives for CS treatment are:
1) standard CS treatment to promote foetal lung maturity
2) high-dose dexamethasone treatment of the mother
or
3) treatment with repeated doses to reduce maternal mor-
bidity and hastening recovery.
Maternal benefit of CS treatment for the HELLP syndrome
was first reported in 1984 [119]. In addition to accelerate
maturation of the foetal lungs, favourable maternal effects
of CS treatment have been suggested: diminished
oedema, inhibited endothelial activation and reduced
endothelial dysfunction, prevention of thrombotic micro-
angiopathic anaemia, and inhibition of cytokine produc-
tion and thereby induce anti-inflammatory effects in the
HELLP syndrome [27]. Benefit from CS treatment of the
HELLP syndrome was reported in a publication from
1993 where less frequent grade III and IV IVH, necrotizing
enterocolitis (NEC), retrolental fibroplasia and fewer neo-
natal deaths were observed [120]. In addition to accelerate
foetal lung maturity, antenatal CS has been used to reduce
the risk of IVH and NEC in selected cases of the HELLP
syndrome with maternal PLT count over 50·109/L
between 24 and 34 weeks' gestation during continuous
maternal and foetal surveillance [121].
Thus, CS treatment of the mother with HELLP looks theo-
retically attractive.
Evaluation of standard CS treatment on maternal HELLP
It remains uncertain if standard CS treatment to induce
foetal lung maturation has been convincingly shown to
benefit the woman with HELLP [9]. A Cochrane analysis
from 2004 concluded that CS treatment did not affect
maternal mortality and outcomes such as placental abrup-
tion, pulmonary oedema and liver complications. There
was a shorter mean duration of hospital stay (4.5 days in
favour of corticosteroids over placebo) and a tendency
toward greater PLT count increase over 48 hours [122]. A
recent review confirmed that CS increased the PLT countBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
Page 9 of 15
(page number not for citation purposes)
without improving maternal morbidity in the HELLP syn-
drome [37]. Thus, standard CS treatment has only minor
clinical effects in the HELLP syndrome. Strong evidence
for recommending standard CS treatment in women with
the HELLP syndrome has not been presented.
High-dose dexamethasone treatment of maternal HELLP
Retrospective and small randomized studies suggested
that the use of high-dose dexamethasone (10 mg dexam-
ethasone every12 hours) in the HELLP syndrome reduced
maternal morbidity and induced more rapid improve-
ment of the PLT counts. Thereby the rate of regional
anaesthesia could be increased, consequently allowing
vaginal delivery [27,87,123-128]. In a publication from
2006 by Martin et al. (based on retrospective analysis and
referring to experience and publications and 2 small ran-
domised studies in the antepartum period that reported
less morbidity in the treatment group), aggressive use of
potent GS was recommended as a cornerstone of manage-
ment for women with the HELLP syndrome class 1 and 2
or for women with class 3 HELLP syndrome accompanied
with epigastric pain, eclampsia, severe hypertension or
evidence of major organ morbidity [7]. CS treatment was
recommended only as short-term intervention. Continua-
tion of pregnancy for more than 48 hours after CS admin-
istration for very preterm HELLP syndrome can lead to
significant maternal and foetal morbidity and mortality
[7,129].
The largest randomized double blind, placebo controlled
(dexamethasone versus placebo) study so far by Fonseca
et al. included 132 women with the HELLP syndrome. The
study included both HELLP occurring in pregnancy (n =
60) and after delivery (n = 72) [130]. This study could not
confirm favorable results of previous small studies. Dex-
amethasone treatment did not reduce maternal complica-
tions (such as acute renal failure, pulmonary oedema and
oliguria). The rates of platelets and fresh frozen plasma
transfusions were not significantly reduced, nor was the
time of recovery of laboratory test shortened, or the dura-
tion of hospital stay. The results of this study did not sup-
port the routine use of high-dose dexamethasone [130].
Summary and general comments on CS therapy in the HELLP 
syndrome
In threatening preterm delivery a single course of CS has
documented clinical benefit for the foetus without
adverse effects. Multiple courses should be avoided,
except well-structured research protocols [131]. Although
CS treatment has been shown to be effective in severe
preeclampsia, it seems to be less beneficial in the HELLP
syndrome [9]. The largest randomized trial on high-dose
dexamethasone did not support high-dose dexametha-
sone treatment of the mother with the HELLP syndrome.
Its routine use is disregarded by Sibai who advocates
standard-dose CS treatment (either 2 doses of betametha-
sone every 12 hours intramuscularly, or 6 mg dexametha-
sone intravenously every 12 hour) to improve perinatal
outcome in the HELLP syndrome diagnosed between 24
and 34 weeks' gestation and then deliver 24 hours after
the last dose of CS [9].
In a recent review, Vidaeff and Yeomas pointed out that
available evidence does not support that CS treatment can
improve the outcome of pregnancies affected by the
HELLP syndrome either antepartum and/or post-partum.
Benefits from CS treatment for disease modification in the
HELLP syndrome should individually be compared with
immediate delivery, the current gold standard [132].
Thus, there is strong evidence for a single course of stand-
ard CS treatment in preterm delivery, including severe
preeclampsia, but no conclusive evidence supporting CS
treatment of the HELLP syndrome.
Practical approach towards a woman with a suspect or diagnosed 
HELLP syndrome
The first step is to evaluate the patient. The clinical mater-
nal status, gestational age (ultrasound determined), pres-
ence of labour and cervical Bishop score should be
determined. The laboratory examination must include
complete blood cell count, in particular PLT count, coag-
ulation parameters, AST, LDH and haptoglobin and urine
examination. Blood pressure measurement, ultrasound
examination and foetal assessment tests (Cardiotocogra-
phy and Doppler examination) are important [5]. The
next step is to stabilize the maternal clinical condition
with intravenous fluids, antihypertensive drugs (e.g.
labetalol or nifedipine) and magnesium sulphate to pre-
vent convulsions [5,7,9,15]. It is of utmost importance to
monitor closely maternal vital signs and fluid balance [5].
We agree with the proposal by Sibai [9] and others [7,133]
who do not generally recommend immediate Caesarean
section, but advocate vaginal or Caesarean delivery 24 to
48 hours after CS treatment for maximum maternal and
foetal benefits. However, according to recent literature
there is no strong evidence for beneficial effects following
CS treatment in the HELLP syndrome. If the HELLP syn-
drome develops before 24 weeks' gestation, termination
of pregnancy should be strongly considered [134].
Other treatment options
Treatment with antithrombin has been suggested as a pos-
sible therapeutic option for preeclampsia [135]. In a ran-
domized study of severe preeclampsia it was shown that
antithrombin supplementation may correct hypercoagu-
lability, stimulate prostacyclin production, regulate
thrombin-induced vasoconstriction, improve foetal status
(improving foetal biophysical profile, decreasing foetal
distress) and promote foetal growth [136]. In contrast to
the use of heparin, antithrombin has not been shown toBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
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increase the risk of bleeding. However, antithrombin
treatment has so far not been investigated in randomized
studies in women with the HELLP syndrome. The poten-
tial benefit from antithrombin treatment of women with
HELLP syndrome might be a reasonable objective to be
tested in future well designed multicenter studies.
It is well documented that glutathione levels are decreased
in the HELLP syndrome. Enhancement of intracellular
glutathione may protect against damage by hydrogen per-
oxide. Normalization of the glutathione levels in patients
with preeclampsia and the HELLP syndrome might be a
promising therapy in the future [137]. Moreover, infusion
of S-nitrosoglutathione in women with severe preeclamp-
sia lowers maternal mean arterial pressure, reduces plate-
let activation and uterine artery resistance without further
compromising foetal Doppler indices [138]. Ruptured
subcapsular liver haematomas must lead to Caesarean
section. Operative treatment is not usually required if
unruptured [38]. Spontaneous rupture of a subcapsular
liver haematoma may be treated by surgery (packing with
gauze is preferable to lobectomy), arterial ligation or
selective arterial embolization or even liver transplanta-
tion [61-63,65,78]. Recombinant factor VIIa is an effective
adjunct in the treatment of preeclamptic patients with
expanding or ruptured subcapsular liver haematoma [64].
Pulmonary oedema may be more effectively treated by
applying early haemodialysis [139]. It is interesting that in
utero exposure of magnesium sulphate may be protective
against development of CP [140,141]. Its neuroprotective
effect has been shown in neonatal animals with experi-
mental brain lesions [94].
Timing and mode of delivery
We have not identified any randomized trial comparing
maternal and neonatal outcome after vaginal delivery or
Caesarean section for women with the HELLP syndrome.
The indication of delivery, timing and method of delivery
of the HELLP syndrome is more or less depending on
experience and local traditions and there is no general
agreement. A woman with a class 3 HELLP syndrome
could await spontaneous onset of delivery at term [15].
Pregnant women with moderate (class 2), complete or
severe (class 1) HELLP syndrome with completed 34
weeks' gestation should be delivered immediately after
control of maternal hypertension [15]. The route of deliv-
ery should be selected on obstetric indications including
cervical status, obstetric history, the maternal and the foe-
tal condition. If the cervix is unfavourable for induction of
labour, cervical ripening should be the first step [21].
Before 34 weeks' gestation, delivery should be chosen if
the maternal condition cannot be controlled rapidly, if
the maternal condition worsens or signs of intrauterine
foetal distress develop. Maternal indications for immedi-
ate delivery include blood pressure > 160/110 mmHg
despite treatment with antihypertensive drugs, persisting
or worsening clinical symptoms, deteriorating renal func-
tion, severe ascites, abruptio placentae, oliguria, pulmonary
oedema or eclampsia [72]. In such cases most clinicians
probably will prefer Caesarean section.
In pregnant women between 24 and 34 weeks' gestation a
full course of CS is advocated after maternal stabilization
(particularly blood pressure and coagulation abnormali-
ties) followed by induced delivery after 24 hours [7,9].
However, as mentioned, the support for this regimen is
weak. Caesarean section should be performed in women
who develop HELLP syndrome before 30 weeks' gestation
[9,142] and in those in whom oligohydramnion and/or
unfavourable Bishop score are diagnosed [9]. Regional
anaesthesia is indicated for cases with PLT counts below
100·109/L. However, epidural anaesthesia is contraindi-
cated if the PLT count is below 75·109/L [9]. Some
authors also claim that regional anaesthesia is contraindi-
cated if the platelet count is below 100·109/L [143]. Plate-
let transfusion prior to Caesarean section has been
suggested for class 1 HELLP syndrome, and for those with
vaginal delivery and PLT count below 20 to 25·109/L
[21]. Antihypertensive drug is administered to keep blood
pressure below 155/105 mmHg, and the woman should
be monitored closely for at least 48 hours after delivery
[10]. Most patients show evidence of resolution during
this time.
Management of post-partum HELLP syndrome
In most women with a HELLP syndrome, the maternal
PLT counts continue to decrease immediately post-par-
tum with an increasing trend on the third day [6]. About
30% of the HELLP syndromes develop after birth; the
majority within the first 48 hours. However, the time of
onset might range from a few hours to 7 days after delivery
[10]. In women with post-partum HELLP syndrome, risk
of renal failure and pulmonary oedema is significantly
increased compared to those with an antenatal onset
[59,86]. Since early post-partum administration of high-
dose CS might accelerate recovery [128], its routine
administration is highly advocated (10 mg of dexametha-
sone every 12 hours) [6,144-146].
However, a randomized study showed that adjunctive use
of intravenous dexamethasone for postpartum patients
with severe preeclampsia did not reduce disease severity
or duration [147]. Moreover, the benefit of dexametha-
sone in post-partum HELLP syndrome was not verified in
a randomized placebo controlled trial on 105 women
with postpartum HELLP syndrome. There was no differ-
ence in maternal morbidity, duration of hospital stay,
need for rescue scheme or the use of blood products
between the groups, nor was there any difference withBMC Pregnancy and Childbirth 2009, 9:8 http://www.biomedcentral.com/1471-2393/9/8
Page 11 of 15
(page number not for citation purposes)
respect to the pattern of PLT count, recovery, AST, LDH,
haemoglobin or diuresis. These findings did not support
the use of dexamethasone in the puerperium for recovery
of women with HELLP [148].
Women with a HELLP syndrome who demonstrate pro-
gressive elevation of bilirubin or creatinine for more than
72 hours after delivery may benefit from plasma exchange
with fresh frozen plasma [149-151]. In the case of contin-
uing haemolysis, persistent thrombocytopenia and hypo-
proteinaemia, post-partum erythrocyte and thrombocyte
substitution, as well as albumin supplementation, are
standard treatment regimens [5,21]. In a recent study of
women with class 1 HELLP syndrome adding of platelet
transfusion to standard CS administration did not
increase the recovery rate [152]. Ertan et al. treated women
with diuresis problems in the postpartum period with
furosemide and applied prophylaxis with antithrombin
or low-dose heparin for DIC [5]. A meta-analysis con-
cluded that furosemide was not beneficial to prevent or
treat acute renal failure in adults [153]. Too little fluid can
exacerbate an already vasoconstricted intravascular vol-
ume and lead to renal injury in severe preeclampsia or in
the HELLP syndrome. A bolus intravenous fluid of 250–
500 ml is advocated if oliguria persists, and, if necessary,
central monitoring of the patient [6].
Some patients with the HELLP syndrome, especially those
with DIC, may demonstrate delayed resolution or even
deterioration in the post-partum period [101]. Therefore,
the use of heparin has been proposed for patients with
preeclampsia, HELLP syndrome and DIC. A retrospective
analysis of women with DIC in the post-partum period
revealed that 6 of 9 developed post-partum bleeding
including retroperitoneal haematoma. Treatment with
heparin was discouraged for post-partum bleeding [84].
Thus, most authors oppose the routine use of heparin.
Risk of recurrence and pre-conceptional counselling
Sibai has shown that oral contraceptives are safe in
women with a prior HELLP syndrome [8]. Women with a
history of the HELLP syndrome carry an increased risk of
at least 20% (range 5–52%) that some form of gestational
hypertension will recur in a subsequent gestation
[7,11,101,142,154].
In a subsequent pregnancy, women with a history of
HELLP syndrome at or before 28 weeks' gestation during
the index pregnancy are at increased risk for several obstet-
ric complications (preterm birth, pregnancy-induced
hypertension and increased neonatal mortality) [154]. In
patients with prior severe, early-onset preeclampsia
thrombophilia screening has been suggested and should
include search for protein S deficiency, activated protein C
resistance (APC resistance), hyperhomocysteinemia and
anti-phospholipid antibodies (both lupus anticoagulant
(LA) and anti-cardiolipin) [155].
Concluding remarks
Different definitions and classifications have up to now
been used to diagnose the HELLP syndrome. This has lim-
ited the usefulness of many clinical reports. The Tennessee
and Mississippi classifications are well suited to facilitate
comparisons. Classifications used in future reports should
be restricted to one of these.
Neither randomized trials nor Cochrane evaluations
regarding delivery in women with the HELLP syndrome
have been performed. In order to reduce the risk of poten-
tially serious complications, there is consensus that early
delivery is indicated when the HELLP syndrome develops
after 34 weeks of pregnancy. Expectant management and
the use of CS in the HELLP syndrome developed prior to
34 weeks of gestation are main controversial issues. There
is no general agreement on timing of delivery and the best
method of delivery. In deliveries in the time-span between
24 and 34 weeks' gestation, a standard CS course is usu-
ally recommended after stabilization of the maternal con-
dition, followed by delivery 24 hours later. Although a
maternal benefit has been demonstrated for patients with
severe preeclampsia, this effect seems to be limited or
lacking in patients with the HELLP syndrome. Repeated
CS dosage and high-dose dexamethasone treatment can at
present not be recommended. There is a definite need
both in antepartum and post-partum HELLP patients for
adequately sized, randomized, placebo-controlled trials
regarding dosage of CS, as well as high-dose dexametha-
sone versus standard CS dosage. Better insight in the com-
plex pathophysiology of the HELLP syndrome may lead to
new treatment alternatives and improved clinical manage-
ment. A well designed multicenter study testing the bene-
fit of antithrombin to counteract DIC in the HELLP
syndrome should be encouraged.
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